

Seonggyu Byeon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4784021/publications.pdf>

Version: 2024-02-01

31
papers

406
citations

933264

10
h-index

794469

19
g-index

31
all docs

31
docs citations

31
times ranked

881
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnostic Value of Ascitic Tumor Markers for Gastric Cancer-associated Malignant Ascites. The Korean Journal of Helicobacter and Upper Gastrointestinal Research, 2022, 22, 38-49.	0.1	3
2	Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer. Oncology, 2021, 99, 365-372.	0.9	6
3	E-Cadherin and Angiopoietin-2 as Potential Biomarkers for Colorectal Cancer With Peritoneal Carcinomatosis. Anticancer Research, 2021, 41, 4497-4504.	0.5	5
4	Reducing tumor invasiveness by ramucirumab and TGF α 2 receptor kinase inhibitor in a diffuse-type gastric cancer patient-derived cell model. Cancer Medicine, 2021, 10, 7253-7262.	1.3	10
5	Comparison of first-line treatments of peripheral T-cell lymphoma according to regimen: A systematic review and meta-analysis. Hematological Oncology, 2021, 39, 664-673.	0.8	8
6	A prospective phase-II trial of biweekly docetaxel plus androgen deprivation therapy in patients with previously-untreated metastatic castration-naïve prostate cancer. BMC Cancer, 2021, 21, 1281.	1.1	3
7	Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests. Clinical Lung Cancer, 2020, 21, e182-e190.	1.1	5
8	Regorafenib in patients with advanced Child-Pugh B hepatocellular carcinoma: A multicentre retrospective study. Liver International, 2020, 40, 2544-2552.	1.9	32
9	Antitumor activity and safety of sirolimus for solid tumors with PIK3CA mutations: A multicenter, open-label, prospective single-arm study (KM 02-01, KCSG UN17-16). Translational Cancer Research, 2020, 9, 3222-3230.	0.4	3
10	Prediction and prevention of central nervous system relapse in patients with extranodal natural killer/T-cell lymphoma. Blood, 2020, 136, 2548-2556.	0.6	17
11	PD-1 inhibitors for non-small cell lung cancer patients with special issues: Real-world evidence. Cancer Medicine, 2020, 9, 2352-2362.	1.3	29
12	Use of Gefitinib in EGFR-Amplified Refractory Solid Tumors: An Open-Label, Single-Arm, Single-Center Prospective Pilot Study. Targeted Oncology, 2020, 15, 185-192.	1.7	5
13	Impact of Prior Ramucirumab Use on Treatment Outcomes of Checkpoint Inhibitors in Advanced Gastric Cancer Patients. Targeted Oncology, 2020, 15, 203-209.	1.7	3
14	Regorafenib in previously treated advanced hepatocellular carcinoma: Impact of prior immunotherapy and adverse events. Liver International, 2020, 40, 2263-2271.	1.9	26
15	Molecular features for selecting Asian metastatic melanoma patients who benefit from check-point inhibitors.. Journal of Clinical Oncology, 2020, 38, e22011-e22011.	0.8	0
16	Phase II study of biweekly docetaxel plus androgen-deprivation therapy (ADT) in patients with previously-untreated, metastatic, prostatic adenocarcinoma.. Journal of Clinical Oncology, 2020, 38, e17580-e17580.	0.8	0
17	Docetaxel rechallenge in metastatic castration-resistant prostate cancer: A retrospective, single-center study. Investigative and Clinical Urology, 2020, 61, 588.	1.0	4
18	Pemetrexed plus erlotinib as a salvage treatment in high EGFR-expressing metastatic colorectal cancer patients following failure of standard chemotherapy: A phase II single-arm prospective study.. Journal of Clinical Oncology, 2020, 38, 104-104.	0.8	0

#	ARTICLE	IF	CITATIONS
19	Clinical Outcomes of EGFR Exon 20 Insertion Mutations in Advanced Non-small Cell Lung Cancer in Korea. <i>Cancer Research and Treatment</i> , 2019, 51, 623-631.	1.3	40
20	Clinical outcomes of EGFR exon 20 insertion in advanced NSCLC in Korea.. <i>Journal of Clinical Oncology</i> , 2018, 36, e21136-e21136.	0.8	0
21	Clinicopathologic Features and Long-Term Outcomes of Elderly Breast Cancer Patients: Experiences at a Single Institution in Korea. <i>Cancer Research and Treatment</i> , 2016, 48, 1382-1388.	1.3	10
22	Warfarin skin necrosis mimicking calciphylaxis in a patient with secondary hyperparathyroidism undergoing peritoneal dialysis. <i>Kidney Research and Clinical Practice</i> , 2016, 35, 55-58.	0.9	3
23	Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis. <i>Medical Oncology</i> , 2016, 33, 97.	1.2	39
24	A Korean single-center, real-world, retrospective study of first-line weekly paclitaxel in patients with metastatic angiosarcoma. <i>Clinical Sarcoma Research</i> , 2016, 6, 8.	2.3	10
25	Two Cases of Small Cell Lung Cancer Transformation from EGFR Mutant Adenocarcinoma During AZD9291 Treatment. <i>Journal of Thoracic Oncology</i> , 2016, 11, e1-e4.	0.5	76
26	Characteristics of Young Korean Metabolically Healthy Obese Patient: Based on Retrospective Analysis of Republic of Korea Navy Soldiers' Medical Examination. <i>Journal of Lipid and Atherosclerosis</i> , 2016, 5, 155.	1.1	0
27	Complete remission in CD30-positive refractory extranodal NK/T-cell lymphoma with brentuximab vedotin. <i>Blood Research</i> , 2015, 50, 254.	0.5	60
28	Phase I trial and pharmacokinetic study of Tanibirumab, a fully human monoclonal antibody to the vascular endothelial growth factor receptor 2 in patients with refractory solid tumors.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2522-2522.	0.8	2
29	The prevalence and prognostic relevance of PD-L1 expression in patients with HPV-negative and HPV-positive oropharyngeal cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e14003-e14003.	0.8	1
30	Placebo-controlled, double-blinded multi-center phase III trial of XELIRI/FOLFIRI plus simvastatin in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 3576-3576.	0.8	3
31	Dynamic serial monitoring of EGFR mutations in plasma DNA samples in EGFR mutant NSCLC patients treated with EGFR TKI.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8078-8078.	0.8	3